C. Madroñal

955 total citations
11 papers, 533 citations indexed

About

C. Madroñal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Madroñal has authored 11 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in C. Madroñal's work include Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (4 papers) and Lung Cancer Research Studies (4 papers). C. Madroñal is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (4 papers) and Lung Cancer Research Studies (4 papers). C. Madroñal collaborates with scholars based in Spain, Netherlands and Italy. C. Madroñal's co-authors include C. Coens, S. Pecorelli, C. Mangioni, J. Baptist Trimbos, Massimo Piergiuseppe Franchi, Saverio Tateo, J. B. Vermorken, P.J. Timmers, Ignace Vergote and Gerardo Zanetta and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Thoracic Oncology.

In The Last Decade

C. Madroñal

10 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Madroñal Spain 4 446 254 176 153 88 11 533
C. Coens Netherlands 3 624 1.4× 344 1.4× 271 1.5× 155 1.0× 83 0.9× 6 673
R. Fossati Italy 8 551 1.2× 479 1.9× 179 1.0× 148 1.0× 51 0.6× 14 704
Alan C. Schlaerth United States 7 465 1.0× 407 1.6× 136 0.8× 112 0.7× 65 0.7× 7 659
M Markman United States 9 329 0.7× 108 0.4× 214 1.2× 145 0.9× 40 0.5× 15 436
Maria Grazia Cantù Italy 9 437 1.0× 171 0.7× 223 1.3× 106 0.7× 47 0.5× 16 574
Jennifer Ducie United States 13 409 0.9× 436 1.7× 54 0.3× 81 0.5× 62 0.7× 16 630
Lucía González‐Cortijo Spain 11 179 0.4× 192 0.8× 94 0.5× 108 0.7× 84 1.0× 26 434
S. Chiara Italy 11 232 0.5× 83 0.3× 184 1.0× 176 1.2× 69 0.8× 22 400
David L. Marchetti United States 12 171 0.4× 138 0.5× 68 0.4× 75 0.5× 54 0.6× 12 293
Diana Lim Singapore 11 234 0.5× 211 0.8× 58 0.3× 52 0.3× 96 1.1× 30 415

Countries citing papers authored by C. Madroñal

Since Specialization
Citations

This map shows the geographic impact of C. Madroñal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Madroñal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Madroñal more than expected).

Fields of papers citing papers by C. Madroñal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Madroñal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Madroñal. The network helps show where C. Madroñal may publish in the future.

Co-authorship network of co-authors of C. Madroñal

This figure shows the co-authorship network connecting the top 25 collaborators of C. Madroñal. A scholar is included among the top collaborators of C. Madroñal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Madroñal. C. Madroñal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Feliú, Jaime, M. J. Safont, Antonieta Salud, et al.. (2009). Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma. Journal of Clinical Oncology. 27(15_suppl). 4119–4119. 1 indexed citations
2.
Paz‐Ares, Luis, J.L. González-Larriba, Núria Viñolas, et al.. (2007). P3-130: A large Spanish experience with erlotinib in advanced non–small cell lung cancer. Journal of Thoracic Oncology. 2(8). S734–S735. 1 indexed citations
3.
Mayordomo, José, et al.. (2007). Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer. Journal of Clinical Oncology. 25(18_suppl). 11049–11049. 2 indexed citations
4.
Feliú, Jaime, Guillermo Martı́n, Javier de Castro, et al.. (2006). Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 58(4). 527–531. 5 indexed citations
5.
Barón, Manuel González, José Ignacio Chacón, Jaime Feliú, et al.. (2005). Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 58(2). 266–271. 3 indexed citations
6.
7.
Castro, Javier de, Serafín Morales, C. Madroñal, et al.. (2004). Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemotherapy and Pharmacology. 55(2). 197–202. 15 indexed citations
8.
Espinosa, Enrique, Serafín Morales, Pablo Borrega, et al.. (2004). Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 54(6). 546–552. 14 indexed citations
9.
Viéitez, José María, Carlos García Girón, C. Madroñal, et al.. (2004). Definitive results of a phase II study with carboplatin (CBDCA) plus etoposide (VP16) and sequential topotecan in small cell lung cancer (SCLC). (an INTER-GON trial). Journal of Clinical Oncology. 22(14_suppl). 7266–7266. 1 indexed citations
10.
Mayordomo, José, et al.. (2004). Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer. Journal of Clinical Oncology. 22(14_suppl). 788–788. 2 indexed citations
11.
Trimbos, J. Baptist, Ignace Vergote, Giorgio Bolis, et al.. (2003). Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. JNCI Journal of the National Cancer Institute. 95(2). 113–125. 489 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Coens Breakdown of academic impact, for papers by R. Fossati Breakdown of academic impact, for papers by Alan C. Schlaerth Breakdown of academic impact, for papers by M Markman Breakdown of academic impact, for papers by Maria Grazia Cantù Breakdown of academic impact, for papers by Jennifer Ducie Breakdown of academic impact, for papers by Lucía González‐Cortijo Breakdown of academic impact, for papers by S. Chiara Breakdown of academic impact, for papers by David L. Marchetti Breakdown of academic impact, for papers by Diana Lim
Rankless by CCL
2026